Land: Canada
Taal: Engels
Bron: Health Canada
AMITRIPTYLINE HYDROCHLORIDE
ANGITA PHARMA INC.
N06AA09
AMITRIPTYLINE
10MG
TABLET
AMITRIPTYLINE HYDROCHLORIDE 10MG
ORAL
100/1000
Prescription
TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0101524001; AHFS:
APPROVED
2018-09-19
_AG-Amitriptyline (Amitriptyline Hydrochloride Tablets)_ _ _ _Page 1 of 32 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AG-AMITRIPTYLINE Amitriptyline Hydrochloride Tablets Tablets, 10 mg, 25 mg, 50 mg and 75 mg, Oral House Standard Antidepressant Angita Pharma Inc. 1310 rue Nobel Boucherville, Québec J4B 5H3, Canada Date of Initial Authorization: June 26, 2018 Date of Revision: March 21, 2023 Submission Control Number: 272524 _AG-Amitriptyline (Amitriptyline _ _Hydrochloride Tablets)_ _ _ _)_ _ _ _Page 2 of 32 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Neurologic 03/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX................................................................... 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ............................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ................................................... Lees het volledige document